RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, delaying generic competition for its blockbuster ATTR-CM drug Vyndamax until 2031. The move preserves ...

Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on ...

Pfizer Philippines, together with healthcare professionals, has launched "For the Reasons that Matter", a public awareness campaign focused on adult respiratory health. Rolling out across the ...

Investors who seek out dividend stocks pay close attention to a company's dividend yield, and high-yield players -- as long ...

Pfizer has reached settlements with three drugmakers to delay US generic competition for its $6.4 billion heart drug Vyndamax until 2031, extending revenue stability amid looming industry pressures.

Republican Wisconsin Sen. Ron Johnson held a hearing probing Biden officials over the handling of COVID-19 vaccine safety ...

BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.